These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
197 related articles for article (PubMed ID: 11514369)
1. Circulating matrix metalloproteinases and their inhibitors in patients with Kawasaki disease. Senzaki H; Masutani S; Kobayashi J; Kobayashi T; Nakano H; Nagasaka H; Sasaki N; Asano H; Kyo S; Yokote Y Circulation; 2001 Aug; 104(8):860-3. PubMed ID: 11514369 [TBL] [Abstract][Full Text] [Related]
2. [Clinical value of serum matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 for the prediction and early diagnosis of coronary artery lesion in patients with Kawasaki disease]. Peng Q; Zhou TF; Chen CH; Hua YM; Liu HM; Hong H; Zhang LY; Wu Q Zhonghua Er Ke Za Zhi; 2005 Sep; 43(9):676-80. PubMed ID: 16191301 [TBL] [Abstract][Full Text] [Related]
3. The pathophysiology of coronary artery aneurysms in Kawasaki disease: role of matrix metalloproteinases. Senzaki H Arch Dis Child; 2006 Oct; 91(10):847-51. PubMed ID: 16990356 [TBL] [Abstract][Full Text] [Related]
4. [Matrix metalloproteinase-1 expression in the circulation of patients with Kawasaki disease and its role in the pathogenesis of coronary artery lesions]. Yang SW; Wang DW; Li J; Qin YM; Wang FM; Cao LM; Zhang LF; Hu Z Zhonghua Er Ke Za Zhi; 2005 Aug; 43(8):612-5. PubMed ID: 16191276 [TBL] [Abstract][Full Text] [Related]
5. Association of Plasma Matrix Metalloproteinase and Tissue Inhibitors of Matrix Metalloproteinase Levels With Adverse Treatment Outcomes Among Patients With Pulmonary Tuberculosis. Kumar NP; Moideen K; Nancy A; Viswanathan V; Thiruvengadam K; Sivakumar S; Hissar S; Nair D; Banurekha VV; Kornfeld H; Babu S JAMA Netw Open; 2020 Dec; 3(12):e2027754. PubMed ID: 33258908 [TBL] [Abstract][Full Text] [Related]
6. Matrix metalloproteinases and their tissue inhibitors in serum and cerebrospinal fluid of patients with amyotrophic lateral sclerosis. Niebroj-Dobosz I; Janik P; Sokołowska B; Kwiecinski H Eur J Neurol; 2010 Feb; 17(2):226-31. PubMed ID: 19796283 [TBL] [Abstract][Full Text] [Related]
8. Profiles of matrix metalloproteinases and their inhibitors in plasma of patients with dementia. Lorenzl S; Buerger K; Hampel H; Beal MF Int Psychogeriatr; 2008 Feb; 20(1):67-76. PubMed ID: 17697439 [TBL] [Abstract][Full Text] [Related]
9. Plasminogen activator inhibitor-1 in patients with Kawasaki disease: diagnostic value for the prediction of coronary artery lesion and implication for a new mode of therapy. Senzaki H; Kobayashi T; Nagasaka H; Nakano H; Kyo S; Yokote Y; Sasakid N Pediatr Res; 2003 Jun; 53(6):983-8. PubMed ID: 12621103 [TBL] [Abstract][Full Text] [Related]
10. Elevated levels of matrix metalloproteinase 9 and tissue inhibitor of metalloproteinase 1 during the acute phase of Kawasaki disease. Chua PK; Melish ME; Yu Q; Yanagihara R; Yamamoto KS; Nerurkar VR Clin Diagn Lab Immunol; 2003 Mar; 10(2):308-14. PubMed ID: 12626459 [TBL] [Abstract][Full Text] [Related]
11. Liver Fibrosis in HCV Monoinfected and HIV/HCV Coinfected Patients: Dysregulation of Matrix Metalloproteinases (MMPs) and Their Tissue Inhibitors TIMPs and Effect of HCV Protease Inhibitors. Latronico T; Mascia C; Pati I; Zuccala P; Mengoni F; Marocco R; Tieghi T; Belvisi V; Lichtner M; Vullo V; Mastroianni CM; Liuzzi GM Int J Mol Sci; 2016 Mar; 17(4):455. PubMed ID: 27023536 [TBL] [Abstract][Full Text] [Related]
12. [Serum interleukin 6 (il-6A) concentration correlates with matrix metalloproteinases and their tissue inhibitors in rheumatoid arthritis]. Klimiuk PA; Sierakowski S; Chwiećko J Pol Arch Med Wewn; 2003 Feb; 109(2):119-23. PubMed ID: 12879774 [TBL] [Abstract][Full Text] [Related]
13. Circulating matrix metalloproteinases and their inhibitors in premature coronary atherosclerosis. Noji Y; Kajinami K; Kawashiri MA; Todo Y; Horita T; Nohara A; Higashikata T; Inazu A; Koizumi J; Takegoshi T; Mabuchi H Clin Chem Lab Med; 2001 May; 39(5):380-4. PubMed ID: 11434385 [TBL] [Abstract][Full Text] [Related]
14. Dynamic changes of matrix metalloproteinases and their tissue inhibitors in severe sepsis. Mühl D; Nagy B; Woth G; Falusi B; Bogár L; Weber G; Lantos J J Crit Care; 2011 Dec; 26(6):550-5. PubMed ID: 21530151 [TBL] [Abstract][Full Text] [Related]
15. [Roles of matrix metalloproteinases, tissue inhibitor of matrix metalloproteinase and hs-CRP in Kawasaki disease]. Chen R; Zhang AR; Zhao XX; Li ZH Zhongguo Dang Dai Er Ke Za Zhi; 2009 Dec; 11(12):989-91. PubMed ID: 20113606 [TBL] [Abstract][Full Text] [Related]
17. Matrix metalloproteinases and their tissue inhibitors in serum and cerebrospinal fluid of patients with moderate and severe traumatic brain injury. Zheng K; Li C; Shan X; Liu H; Fan W; Wang Z; Zheng P Neurol India; 2013; 61(6):606-9. PubMed ID: 24441327 [TBL] [Abstract][Full Text] [Related]
18. Clinical Investigation of Matrix Metalloproteinases, Tissue Inhibitors of Matrix Metalloproteinases, and Matrix Metalloproteinase/Tissue Inhibitors of Matrix Metalloproteinase Complexes and Their Networks in Apical Periodontitis. Martinho FC; Teixeira FF; Cardoso FG; Ferreira NS; Nascimento GG; Carvalho CA; Valera MC J Endod; 2016 Jul; 42(7):1082-8. PubMed ID: 27188765 [TBL] [Abstract][Full Text] [Related]
19. Matrix metalloproteinases and their tissue inhibitors (TIMPs) in Plasmodium falciparum malaria: serum levels of TIMP-1 are associated with disease severity. Dietmann A; Helbok R; Lackner P; Issifou S; Lell B; Matsiegui PB; Reindl M; Schmutzhard E; Kremsner PG J Infect Dis; 2008 Jun; 197(11):1614-20. PubMed ID: 18700258 [TBL] [Abstract][Full Text] [Related]
20. Serum matrix metalloproteinases and tissue inhibitors of metalloproteinases in ankylosing spondylitis: MMP-3 is a reproducibly sensitive and specific biomarker of disease activity. Chen CH; Lin KC; Yu DT; Yang C; Huang F; Chen HA; Liang TH; Liao HT; Tsai CY; Wei JC; Chou CT Rheumatology (Oxford); 2006 Apr; 45(4):414-20. PubMed ID: 16287916 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]